General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 531: Which immunosuppressant drug inhibits the mammalian target of rapamycin (mTOR) pathway and prevents T-cell proliferation?

A. Sirolimus (Correct Answer)
B. Azathioprine
C. Cyclosporine
D. Tacrolimus

Explanation: ***Sirolimus*** - **Sirolimus** (also known as rapamycin) is a macrolide lactone that specifically targets the **mTOR** pathway by binding to FKBP-12, forming a complex that inhibits mTOR [3]. - Inhibition of the **mTOR** pathway prevents **T-cell proliferation**, B-cell proliferation, and antibody production, thus acting as a potent immunosuppressant often used in transplant medicine [3], [4]. *Azathioprine* - **Azathioprine** is a purine analog that acts as an antimetabolite, ultimately inhibiting **DNA synthesis** and thus suppressing the proliferation of rapidly dividing cells, including lymphocytes. - It does not directly inhibit the **mTOR** pathway; its mechanism involves interfering with the synthesis of genetic material. *Cyclosporine* - **Cyclosporine** is a calcineurin inhibitor that binds to cyclophilin, preventing the activation of **calcineurin** [1]. - Inhibition of **calcineurin** blocks the dephosphorylation of **NFAT**, thereby preventing its translocation to the nucleus and subsequent transcription of IL-2 and other cytokine genes essential for T-cell activation [1]. *Tacrolimus* - **Tacrolimus** is also a **calcineurin inhibitor**, similar to cyclosporine, but it binds to FKBP-12 instead of cyclophilin [2]. - This binding prevents the activation of **calcineurin**, which in turn inhibits the production of **IL-2** and other cytokines necessary for T-cell proliferation and activation [2].

Question 532: For a patient with high altitude sickness, evaluate the use of acetazolamide in shifting the oxygen-hemoglobin dissociation curve.

A. Shifts left; increases oxygen affinity
B. Shifts right; decreases oxygen affinity (Correct Answer)
C. No effect on the curve
D. Shifts right; increases oxygen affinity

Explanation: ***Shifts right; decreases oxygen affinity*** - Acetazolamide inhibits **carbonic anhydrase**, leading to a **metabolic acidosis** due to bicarbonate excretion by the kidneys. - This acidosis, along with the increase in **2,3-BPG** (due to hypoxia), causes the **oxygen-hemoglobin dissociation curve to shift right**, facilitating **oxygen unloading** to tissues. *Shifts left; increases oxygen affinity* - A left shift indicates increased oxygen affinity, which would **impair oxygen release** to hypoxic tissues in high altitude sickness. - This occurs with **alkalosis** or decreased temperature, which is opposite to the effect of acetazolamide. *No effect on the curve* - This is incorrect as acetazolamide's physiological effects, particularly the induced **acidosis**, are known to influence the oxygen-hemoglobin dissociation curve. - The drug's mechanism of action directly alters blood pH and indirectly affects **2,3-BPG** levels. *Shifts right; increases oxygen affinity* - Although acetazolamide does cause a **right shift** (decreasing affinity), saying it *increases* oxygen affinity is contradictory. - A right shift by definition signifies **decreased hemoglobin affinity** for oxygen, which is beneficial in high altitude conditions.

Question 533: How does the immunomodulatory effect of corticosteroids contribute to their role in the treatment of severe COVID-19?

A. Suppresses cytokine storm, reducing inflammation (Correct Answer)
B. Enhances antibody production against the virus
C. Directly inhibits viral replication
D. Increases ACE2 receptor expression, potentially facilitating viral entry

Explanation: ***Suppresses cytokine storm, reducing inflammation*** - Corticosteroids like **dexamethasone** are potent anti-inflammatory agents that reduce the production and activity of various **pro-inflammatory cytokines** (e.g., IL-6, TNF-α) central to the **cytokine storm** in severe COVID-19. - By dampening this excessive immune response, corticosteroids mitigate **acute respiratory distress syndrome (ARDS)** and systemic organ damage, thereby improving survival. *Enhances antibody production against the virus* - Corticosteroids are **immunosuppressive** and generally *reduce* antibody production, rather than enhancing it. - Their primary benefit in COVID-19 is related to controlling hyperinflammation, not bolstering the adaptive immune response. *Directly inhibits viral replication* - Corticosteroids do not possess direct antiviral properties; they do not target or inhibit the **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)** replication cycle. - Antiviral medications, such as remdesivir, are designed for direct viral inhibition. *Increases ACE2 receptor expression, potentially facilitating viral entry* - There is no evidence to suggest that corticosteroids significantly increase **ACE2 receptor expression** in a manner that would facilitate viral entry in COVID-19 patients. - While immune responses can influence cellular receptor expression, the therapeutic benefit of corticosteroids in severe COVID-19 outweighs any theoretical concern regarding ACE2.

Question 534: The synthesis of which compound is directly inhibited by statins in cholesterol-lowering therapy?

A. Cholesterol
B. Mevalonate (Correct Answer)
C. Fatty acids
D. Amino acids

Explanation: ***Mevalonate*** - Statins **inhibit HMG-CoA reductase**, the rate-limiting enzyme in the **mevalonate pathway**. - This inhibition directly blocks the conversion of **HMG-CoA to mevalonate**, which is a crucial precursor for cholesterol synthesis. *Cholesterol* - While statins ultimately reduce **cholesterol synthesis**, they do so indirectly by inhibiting an upstream precursor in the pathway. - The direct product whose synthesis is blocked by statin action on HMG-CoA reductase is mevalonate, not cholesterol itself. *Fatty acids* - **Fatty acid synthesis** primarily involves enzymes such as **acetyl-CoA carboxylase** and **fatty acid synthase**, which are not directly targeted by statins. - Statins specifically affect the **mevalonate pathway**, which is distinct from fatty acid synthesis. *Amino acids* - **Amino acid synthesis** pathways are entirely different from the cholesterol synthesis pathway and involve various specific enzymes and substrates. - Statins have no direct inhibitory effect on the synthesis of **amino acids**.

Question 535: Which enzyme is inhibited by the drug allopurinol in the treatment of gout?

A. Xanthine oxidase (Correct Answer)
B. Adenosine deaminase
C. Hypoxanthine-guanine phosphoribosyltransferase
D. Phosphoribosyl pyrophosphate synthetase

Explanation: ***Xanthine oxidase*** - **Allopurinol** is a **purine analogue** that acts as a competitive inhibitor of **xanthine oxidase**. - By inhibiting this enzyme, allopurinol prevents the conversion of **hypoxanthine** and **xanthine** to **uric acid**, thereby lowering serum urate levels and preventing acute gout attacks. *Adenosine deaminase* - This enzyme is involved in the metabolism of **adenosine** and **deoxyadenosine**. - Its deficiency leads to **severe combined immunodeficiency (SCID)**, and it is not targeted by allopurinol. *Hypoxanthine-guanine phosphoribosyltransferase* - This enzyme is crucial in the **purine salvage pathway**, recycling hypoxanthine and guanine back into nucleotides. - A deficiency in this enzyme is associated with **Lesch-Nyhan syndrome**, a severe disorder characterized by hyperuricemia and neurological dysfunction. *Phosphoribosyl pyrophosphate synthetase* - This enzyme catalyzes the synthesis of **5-phosphoribosyl-1-pyrophosphate (PRPP)**, a key precursor in both *de novo* purine synthesis and the purine salvage pathway. - Overactivity of this enzyme can lead to **hyperuricemia**, but it is not directly inhibited by allopurinol.

Question 536: A patient with osteoporosis is given a drug that acts as a monoclonal antibody against RANK ligand (RANKL). Which drug is appropriate?

A. Alendronate
B. Denosumab (Correct Answer)
C. Raloxifene
D. Zoledronic acid

Explanation: ***Denosumab*** - **Denosumab** is a **monoclonal antibody** that specifically targets and inhibits **RANKL**. - By binding to **RANKL**, denosumab prevents its interaction with **RANK** on osteoclast precursors and mature osteoclasts, thereby inhibiting osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone density. *Alendronate* - **Alendronate** is a **bisphosphonate**, a class of drugs that inhibit **osteoclast activity** by embedding into the bone matrix and inducing osteoclast apoptosis. - Its mechanism of action is distinct from targeting RANKL. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)**. - It acts as an **estrogen agonist** in bone, helping to prevent bone loss, but its mechanism does not involve direct RANKL inhibition. *Zoledronic acid* - **Zoledronic acid** is also a **bisphosphonate**, similar to alendronate, and is administered intravenously. - It inhibits bone resorption by inducing **osteoclast apoptosis** and interfering with the **mevalonate pathway**, not by blocking RANKL.

Question 537: What is the primary reason for choosing clopidogrel over aspirin in a patient with a history of gastrointestinal bleeding?

A. More effective in preventing cardiovascular events
B. Different mechanism of action
C. Lower risk of gastrointestinal bleeding (Correct Answer)
D. Longer half-life allowing once daily dosing

Explanation: ***Lower risk of gastrointestinal bleeding*** - Clopidogrel is an **antiplatelet agent** that offers a lower risk of **upper gastrointestinal bleeding** compared to aspirin, which directly inhibits COX-1 and can lead to gastric mucosal damage. - In patients with a history of GI bleeding, using clopidogrel helps to reduce the risk of **recurrent bleeding events** while still providing antithrombotic benefits. *More effective in preventing cardiovascular events* - While clopidogrel is effective in preventing cardiovascular events, its primary advantage over aspirin in a patient with a history of GI bleeding is not superior efficacy, but rather its **safer GI profile**. - For many indications, aspirin and clopidogrel have **comparable efficacy** in preventing cardiovascular events, but their safety profiles differ significantly, particularly regarding GI side effects. *Different mechanism of action* - Clopidogrel is a **P2Y12 inhibitor**, preventing ADP-induced platelet aggregation, while aspirin inhibits **cyclooxygenase (COX)**, reducing thromboxane A2 production. - Although the mechanism of action is different, this alone is not the primary reason for choosing clopidogrel in the context of a patient's **GI bleeding history**. *Longer half-life allowing once daily dosing* - While clopidogrel's **once-daily dosing** is a benefit for patient adherence, aspirin can also be dosed once daily for antiplatelet effect, and its bioavailability is high. - The convenience of once-daily dosing does not outweigh the critical consideration of **GI safety** in a patient with a history of gastrointestinal bleeding.

Question 538: MOA of Teduglutide in short bowel syndrome?

A. GLP-2 analog (Correct Answer)
B. 5-HT1A receptor antagonist
C. GLP-1 receptor agonist
D. C-peptide analog

Explanation: ***GLP-2 analog*** - Teduglutide is a **glucagon-like peptide-2 (GLP-2) analog** that binds to and activates GLP-2 receptors. - This activation promotes **intestinal adaptation** by enhancing mucosal growth, increasing nutrient absorption, and improving fluid balance in patients with short bowel syndrome. *5-HT1A receptor antagonist* - 5-HT1A receptor antagonists are primarily used in conditions related to **serotonin pathways**, such as anxiety or depression. - They do not have a direct mechanism to address the **malabsorption** issues seen in short bowel syndrome. *GLP-1 receptor agonist* - GLP-1 receptor agonists are primarily used in the management of **type 2 diabetes** to enhance insulin secretion and reduce glucagon levels. - While GLP-1 and GLP-2 are related, GLP-1 does not have the same direct **trophic and restorative effects** on the intestinal mucosa as GLP-2. *C-peptide analog* - C-peptide is a byproduct of **insulin production** and its analogs have been studied for potential effects on diabetic neuropathy or nephropathy, but not for intestinal adaptation. - It does not play a direct role in regulating **intestinal growth** or nutrient absorption in the context of short bowel syndrome.

Question 539: What is the primary mechanism by which colchicine exerts its anti-inflammatory effects in acute gout?

A. Acts by inhibiting neutrophil migration (Correct Answer)
B. Acts primarily as a uricosuric agent
C. Is the first-line treatment for chronic gout management
D. Has no effect on microtubule function

Explanation: ***Acts by inhibiting neutrophil migration*** - Colchicine primarily functions by **disrupting microtubule formation** in neutrophils, which impairs their chemotaxis and migration to sites of inflammation. - This inhibition of neutrophil activity is crucial in dampening the **inflammatory response** triggered by uric acid crystals in acute gout. *Acts primarily as a uricosuric agent* - While other medications like **probenecid** are uricosuric and increase uric acid excretion, colchicine does not have this primary mechanism of action. - Its main anti-inflammatory effect is independent of uric acid metabolism or excretion. *Is the first-line treatment for chronic gout management* - Colchicine is effective for **acute gout attacks** and as a prophylactic against attacks during initiation of urate-lowering therapy. - However, **allopurinol** and **febuxostat** are the first-line treatments for chronic gout because they reduce uric acid production. *Has no effect on microtubule function* - This statement is incorrect; colchicine's entire mechanism of action is dependent on its ability to **bind to tubulin** and inhibit microtubule polymerization. - This disruption of microtubules is responsible for its anti-inflammatory effects and also its common side effects.

Question 540: What is the PRIMARY vascular function of PGI2 (prostacyclin)?

A. Promotes platelet aggregation and causes vasoconstriction
B. Acts primarily as a bronchoconstrictor
C. Stimulates inflammatory cell chemotaxis
D. Inhibits platelet aggregation and causes vasodilation (Correct Answer)

Explanation: ***Inhibits platelet aggregation and causes vasodilation*** - **PGI2 (prostacyclin)** is a potent **vasodilator** that relaxes smooth muscle in blood vessels, increasing blood flow. - It also effectively **inhibits platelet aggregation**, preventing the formation of blood clots. *Promotes platelet aggregation and causes vasoconstriction* - This describes the primary actions of **thromboxane A2 (TXA2)**, not PGI2. - TXA2 is produced by platelets and plays a key role in **hemostasis** by constricting blood vessels and promoting platelet clumping. *Acts primarily as a bronchoconstrictor* - While some prostaglandins can affect bronchial tone, **PGI2's primary vascular role** is vasodilation and anti-aggregation. - **Leukotrienes** and certain **prostaglandins (e.g., PGD2, PGF2α)** are more classically associated with bronchoconstriction. *Stimulates inflammatory cell chemotaxis* - This is primarily a function of other inflammatory mediators such as **leukotriene B4 (LTB4)** and **C5a anaphylatoxin**. - While other eicosanoids can indirectly influence inflammation, **PGI2's main actions** are vascular and anti-platelet.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free